Neuroscience
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS):
ClinicalTrials.gov Description
===
Corporate press release
===
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...
- Post Tysabri (natalizumab): What Choices In M.s. Treatment?
The Consumer: Exploring Choices for M.S. By MARY DUENWALD The New York Times 15 March 2005 [snip] An estimated 5,000 patients who had been taking Tysabri since the Food and Drug Administration approved it in late November are now advised to see their...
- Multiple Sclerosis And Tysabri: Fda
From the FDA: FOR IMMEDIATE RELEASE P04-107 November 23, 2004 Full press release Media Inquiries: 301-827-6242 Consumer Inquiries: 888-INFO-FDA First Monoclonal Antibody Treatment For Multiple Sclerosis Approved FDA today licensed a...
- Multiple Sclerosis And Antegren/tysabri
From the CBC:Health Canada fast tracks review of multiple sclerosis drug Last Updated Mon, 22 Nov 2004 21:28:46 EST TORONTO - Some Canadians with multiple sclerosis are encouraged by the early results of a study on a new kind of treatment for the...
Neuroscience
Multiple Sclerosis (MS): The SURPASS Clinical Trial
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS):
ClinicalTrials.gov Description
===
Corporate press release
===
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...
- Post Tysabri (natalizumab): What Choices In M.s. Treatment?
The Consumer: Exploring Choices for M.S. By MARY DUENWALD The New York Times 15 March 2005 [snip] An estimated 5,000 patients who had been taking Tysabri since the Food and Drug Administration approved it in late November are now advised to see their...
- Multiple Sclerosis And Tysabri: Fda
From the FDA: FOR IMMEDIATE RELEASE P04-107 November 23, 2004 Full press release Media Inquiries: 301-827-6242 Consumer Inquiries: 888-INFO-FDA First Monoclonal Antibody Treatment For Multiple Sclerosis Approved FDA today licensed a...
- Multiple Sclerosis And Antegren/tysabri
From the CBC:Health Canada fast tracks review of multiple sclerosis drug Last Updated Mon, 22 Nov 2004 21:28:46 EST TORONTO - Some Canadians with multiple sclerosis are encouraged by the early results of a study on a new kind of treatment for the...